SOURCE-LINKED STUDY SUMMARY
Oral orforglipron 17.2 mg versus oral semaglutide 25 mg in adults with type 2 diabetes and BMI ≥25kg/m2: an indirect treatment comparison
Sponsor announcement summarizedQuality not appraised
- What was studied
- An EASD conference analysis indirectly compared oral GLP-1 treatments using ACHIEVE-3 and PIONEER PLUS data.
- Who / model studied
- Adults with type 2 diabetes and BMI ≥25 kg/m². The analyzed sample size was not verified from the full poster.
- Studied dose & schedule
- Orforglipron 17.2 mg versus oral semaglutide 25 mg; outcomes compared at 52 weeks.
- What the study found
- Lilly reported an estimated 1.5-percentage-point advantage in weight loss and 0.3-percentage-point greater A1C reduction with orforglipron. These are between-treatment differences, not total reductions.
- Limitations & context
- Indirect, sponsor-reported comparison, not a head-to-head trial of these doses. Estimates assume continued treatment without additional glucose-lowering medication. Cross-trial differences may remain. Full poster and comparative safety were not reviewed; findings should not be generalized to people without diabetes.
Read summary source ↗ · Prepared 9/29/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: sponsor announcement, full poster not reviewed. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.